SEC Form 4 · accession 0001213900-18-004250
ORAMED PHARMACEUTICALS INC. · ORMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua Hexter
Officer — Chief Operating Officer
Period of report
Apr 8, 2018
Accepted (ET)
Apr 10, 2018 · 5:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001176309
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $7.05 | Apr 8, 2018 | A | 30,000 | A | — | Apr 8, 2028 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The Stock Option will vest in 4 equal installments of 7,500 on each of April 1, 2019, April 1, 2020, April 1, 2021 and April 1, 2022.